Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics develops cancer immunotherapies using its Boltbody™ Immune-Stimulating Antibody Conjugate platform and myeloid-biology programs. Company updates focus on BDC-4182, a next-generation claudin 18.2 ISAC clinical candidate for gastric and gastroesophageal cancers, along with BDC-3042, a Dectin-2 agonist antibody, and preclinical ISAC programs targeting CEA and PD-L1.
Recurring news also includes clinical and preclinical data presentations, quarterly financial results, cash runway commentary, collaboration activity with Genmab and Toray, partnering process disclosures for pipeline assets, conference participation, and cost-control actions tied to the company’s oncology research and development strategy.
Bolt Biotherapeutics (Nasdaq:BOLT) reported Q1 2026 results and a business update. Collaboration revenue was $26,000 versus $1.2 million in Q1 2025. R&D expenses fell to $4.8 million and G&A to $2.8 million, reducing loss from operations to $7.6 million. Cash and investments totaled $23.9 million, expected to fund operations into 2027, including BDC-4182 Phase 1/2 dose escalation. Initial clinical data from BDC-4182 in gastric and gastroesophageal cancer are anticipated in 3Q 2026. Two additional ISAC programs targeting CEA and PD-L1 remain on hold pending BDC-4182 proof-of-concept.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q4 and full-year 2025 results and a development update. Key points: BDC-4182, a Boltbody ISAC targeting claudin 18.2, is in Phase 1 dose escalation with initial clinical data expected in 3Q 2026. Cash, cash equivalents, and marketable securities were $31.8 million as of December 31, 2025, which the company expects will fund milestones into 2027. Collaboration revenue totaled $2.5 million in Q4 2025; full-year R&D and G&A expenses declined versus 2024 following restructuring.
Bolt Biotherapeutics (Nasdaq: BOLT) announced management will participate in two March 2026 investor events: a company presentation at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:50 a.m. EST and one‑on‑one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026.
Bolt Biotherapeutics (Nasdaq: BOLT) reported third quarter 2025 results and a business update on Nov 12, 2025. Key clinical milestone: initial clinical data for BDC-4182 Phase 1 (gastric/gastroesophageal cancer) is expected in 3Q 2026. Cash, cash equivalents, and marketable securities totaled $38.8 million as of Sept 30, 2025, and are expected to fund milestones into 2027. Third-quarter collaboration revenue was $2.2M vs. $1.1M in 3Q24. R&D expense decreased to $6.5M from $13.8M year-over-year; G&A was $3.3M. Loss from operations improved to $7.7M from $16.4M. Company presented preclinical ISAC data at SITC and continues collaborations with Genmab and Toray.
Bolt Biotherapeutics (Nasdaq: BOLT) has announced updates regarding its Phase 1 dose escalation study of BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2 for cancer treatment. Due to strong immune responses observed at initial dose levels, the company is modifying the clinical trial protocol to implement step-up dosing, delaying initial clinical data release to Q3 2026.
To preserve capital, Bolt is implementing a 50% workforce reduction, which will extend their cash runway into 2027. The company will maintain focus on advancing BDC-4812 clinically and supporting their ISAC collaborations to enhance shareholder value.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2025 financial results and business updates. The company's lead candidate, BDC-4182, a next-generation claudin 18.2 ISAC, has entered Phase 1 dose-escalation studies for gastric and gastroesophageal cancer. The company reported $48.5 million in cash as of June 30, 2025, expected to fund operations through mid-2026.
Q2 financial highlights include collaboration revenue of $1.8 million, reduced R&D expenses of $7.5 million (down from $15.4M in Q2 2024), and G&A expenses of $3.5 million (down from $4.9M). The company completed a 1:20 reverse stock split on June 6, 2025, regaining Nasdaq compliance. Bolt continues collaborations with Genmab and Toray while seeking a partner for BDC-3042, which showed partial response in lung cancer patients.
Bolt Biotherapeutics (NASDAQ: BOLT) has announced a key opinion leader (KOL) conference call and webcast scheduled for May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET. The event will feature Dr. Ecaterina Dumbrava from MD Anderson Cancer Center, who will discuss the Phase 1 dose-escalation clinical study results of BDC-3042 previously presented at the AACR Annual Meeting in April 2025.
During the call, Bolt's management team will also provide updates on BDC-3042 partnering plans, BDC-4182 clinical development, and first quarter 2025 financial results. A Q&A session will follow the presentations. The event will be accessible via webcast, with a replay available on the company's investor relations website.
Bolt Biotherapeutics has unveiled promising preclinical results for its next-generation Boltbody™ ISACs targeting CEA and PD-L1 at the AACR Annual Meeting 2025. The company's CEA-targeted ISAC demonstrated complete responses in mice and showed good tolerance in non-human primates (NHPs) up to 15 mg/kg.
The CEA ISAC features a novel human antibody that targets CEACAM-5, commonly found in gastrointestinal cancers. Key findings include enhanced phagocytosis of CEA-positive tumor cells and stimulation of immune-activating cytokines.
The PD-L1 ISAC showed remarkable results by:
- Directly activating and reprogramming PD-L1-expressing myeloid cells
- Achieving complete regressions in models resistant to conventional treatments
- Demonstrating favorable safety profiles in NHP studies
Both ISACs showed potential for durable responses through immunological memory, supporting their use in combination with standard-of-care therapies.
Bolt Biotherapeutics (BOLT) announced promising results from its Phase 1 dose-escalation study of BDC-3042, a novel immunotherapy for cancer treatment, at the AACR Annual Meeting 2025. The study enrolled 17 patients across seven dose cohorts with various tumor types.
Key findings include:
- BDC-3042 was well-tolerated up to 10 mg/kg q2w with no dose-limiting toxicities
- No drug-related serious adverse events or treatment discontinuations reported
- Most common drug-related adverse events: fatigue, flatulence, and nausea (12% each)
- Demonstrated favorable pharmacokinetics and biological activity
- Showed anti-tumor activity, including an unconfirmed partial response in NSCLC
- 80% of evaluable patients achieved stable disease or better
The company is now seeking partnership opportunities to advance BDC-3042's development, particularly focusing on NSCLC and post-immunotherapy settings.